Common-Size Income Statement
Paying user area
Try for free
Gilead Sciences Inc. pages available for free this week:
- Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Liquidity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Analysis of Geographic Areas
- Enterprise Value to FCFF (EV/FCFF)
- Price to FCFE (P/FCFE)
- Selected Financial Data since 2005
- Net Profit Margin since 2005
- Price to Operating Profit (P/OP) since 2005
- Price to Sales (P/S) since 2005
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Gilead Sciences Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
Income statement item | Description | The company |
---|---|---|
Operating income | The net result for the period of deducting operating expenses from operating revenues. | Gilead Sciences Inc. operating income as a percentage of product sales decreased from 2021 to 2022 but then slightly increased from 2022 to 2023. |
Income before income taxes | Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. | Gilead Sciences Inc. income before income taxes as a percentage of product sales decreased from 2021 to 2022 but then slightly increased from 2022 to 2023. |
Net income attributable to Gilead | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. | Gilead Sciences Inc. net income attributable to Gilead as a percentage of product sales decreased from 2021 to 2022 but then increased from 2022 to 2023 not reaching 2021 level. |